

Date: 14 February 2019

To: Dr. Ron Wald, St. Michael's Hospital

CTO Project ID: 0761

Study Title: STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial

Sponsor Study ID: NCT02568722

Study Sponsor: St. Michael's Hospital

Application Type: Centre Continuing Review Application

Review Type: Delegated

Date Approval Issued: 14/Feb/2019

Approval Expiry Date: 23/Feb/2020

Dear Dr. Ron Wald,

The Unity Health Toronto Research Ethics Board has reviewed the application. This study, including all currently approved documents, has been reapproved until the expiry date noted above. This letter will serve as an extension of the REB approval for the study for a period of 12 months effective from February 23, 2019 - February 23, 2020. Continuation beyond that date will require further review of REB approval.

REB members involved in the research project do not participate in the review, discussion or decision.

Unity Health Toronto Research Ethics Board operates in compliance with, and is constituted in accordance with, the requirements of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2); the International Conference on Harmonisation Good Clinical Practice Consolidated Guideline (ICH GCP); Part C, Division 5 of the Food and Drug Regulations; Part 4 of the Natural Health Products Regulations; Part 3 of the Medical Devices Regulations and the provisions of the Ontario Personal Health Information Protection Act (PHIPA 2004) and its applicable regulations. Unity Health Toronto Research Ethics Board is qualified through the CTO REB Qualification Program and is registered with the U.S. Department of Health and Human Services (DHHS) Office for Human Research Protection (OHRP).

Please do not hesitate to contact us if you have any questions.

Sincerely,

Philip Berger Michael Szego Michael Heffer
Vice chair REB Vice chair REB Vice Chair REB